These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 32516031)

  • 1. Tele-rounding in a university hospital pulmonary ward during the COVID-19 pandemic: a pilot study.
    Renner A; Paajanen J; Reijula J
    Infect Dis (Lond); 2020 Sep; 52(9):669-670. PubMed ID: 32516031
    [No Abstract]   [Full Text] [Related]  

  • 2. Dermatologists may need to pay more attention to herpes zoster during the pandemic of COVID-19.
    Wang B; Guo S; Yao Y; Li Y; Zhang G
    Infect Dis (Lond); 2020; 52(12):917-918. PubMed ID: 32697129
    [No Abstract]   [Full Text] [Related]  

  • 3. Lower nasopharyngeal viral load during the latest phase of COVID-19 pandemic in a Northern Italy University Hospital.
    Clementi N; Ferrarese R; Tonelli M; Amato V; Racca S; Locatelli M; Lippi G; Silvestri G; Clementi M; Mancini N
    Clin Chem Lab Med; 2020 Aug; 58(9):1573-1577. PubMed ID: 32598306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot virtual clerkship curriculum during the COVID-19 pandemic: Podcasts, peers and problem-solving.
    Geha R; Dhaliwal G
    Med Educ; 2020 Sep; 54(9):855-856. PubMed ID: 32418290
    [No Abstract]   [Full Text] [Related]  

  • 5. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.
    Cantini F; Niccoli L; Nannini C; Matarrese D; Natale MED; Lotti P; Aquilini D; Landini G; Cimolato B; Pietro MAD; Trezzi M; Stobbione P; Frausini G; Navarra A; Nicastri E; Sotgiu G; Goletti D
    J Infect; 2020 Oct; 81(4):647-679. PubMed ID: 32592703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predominance of hospital-acquired bloodstream infection in patients with Covid-19 pneumonia.
    Engsbro AL; Israelsen SB; Pedersen M; Tingsgaard S; Lisby G; Andersen CØ; Benfield T
    Infect Dis (Lond); 2020; 52(12):919-922. PubMed ID: 32779951
    [No Abstract]   [Full Text] [Related]  

  • 7. COVID-19: associated morbidity and mitigation strategies.
    Mahmood SN; Woods CJ; Chan CM
    Infect Dis (Lond); 2020; 52(12):923-926. PubMed ID: 32726166
    [No Abstract]   [Full Text] [Related]  

  • 8. Viral aetiology and clinical characteristics of acute respiratory tract infections in Shenzhen during epidemic of coronavirus disease 2019.
    Zhang D; Jiang Y; Hua J; Liu Q; Wen W; Zhu M; Du J; Liu H
    Infect Dis (Lond); 2020 Aug; 52(8):590-592. PubMed ID: 32452728
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenges in COVID-19: is pulmonary thromboembolism related to overall severity?
    Bellieni A; Intini E; Taddei E; Baldi F; Larosa L; Murri R; Richeldi L; Bernabei R; Cauda R; Landi F; Corbo GM; Fantoni M
    Infect Dis (Lond); 2020 Aug; 52(8):585-589. PubMed ID: 32476551
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study.
    Pallotto C; Suardi LR; Esperti S; Tarquini R; Grifoni E; Meini S; Valoriani A; Di Martino S; Cei F; Sisti E; Piani F; Botta A; Salomoni E; Baragli F; Blanc P
    Infect Dis (Lond); 2020 Sep; 52(9):675-677. PubMed ID: 32543971
    [No Abstract]   [Full Text] [Related]  

  • 11. Laboratory abnormalities related to prolonged hospitalization in COVID-19.
    Tezcan ME; Doğan Gökçe G; Ozer RS
    Infect Dis (Lond); 2020 Sep; 52(9):666-668. PubMed ID: 32543300
    [No Abstract]   [Full Text] [Related]  

  • 12. A familial cluster of severe coronavirus disease 2019 that required intubation of all family members.
    Katsuno T; Suzuki M; Ishikane M; Kinoshita N; Tsukada A; Morita C; Kusaba Y; Sakamoto K; Yamaguchi Y; Tsujimoto Y; Hashimoto M; Terada J; Takasaki J; Izumi S; Okuhama A; Ide S; Moriyama Y; Matsuda K; Takamatsu Y; Mitsuya H; Hojo M; Sugiyama H
    Infect Dis (Lond); 2020 Oct; 52(10):755-758. PubMed ID: 32615051
    [No Abstract]   [Full Text] [Related]  

  • 13. Tocilizumab for COVID-19: a real 'miracle drug'?
    Nasim S; Hashmi SH; Azim D; Kumar S; Nasim J
    Infect Dis (Lond); 2020 Sep; 52(9):681-682. PubMed ID: 32644027
    [No Abstract]   [Full Text] [Related]  

  • 14. Extension of COVID-19 pulmonary parenchyma lesions based on real-life visual assessment on initial chest CT is an independent predictor of poor patient outcome.
    Grégory J; Raynaud L; Galy A; Corre F; Bijot JC; Nguyen Y; Vilgrain V
    Infect Dis (Lond); 2020 Nov; 52(11):838-840. PubMed ID: 32657190
    [No Abstract]   [Full Text] [Related]  

  • 15. Early experience with COVID-19 patients at academic hospital in Southwestern United States.
    Shekhar R; Sheikh AB; Upadhyay S; Atencio J; Kapuria D
    Infect Dis (Lond); 2020 Aug; 52(8):596-599. PubMed ID: 32476537
    [No Abstract]   [Full Text] [Related]  

  • 16. A Moderate Case of COVID-19 Viral Pneumonia During the SARS-CoV-2 Pandemic.
    Spinner CD; Schuldt A; Schuster J
    Dtsch Arztebl Int; 2020 Mar; 117(13):219. PubMed ID: 32343659
    [No Abstract]   [Full Text] [Related]  

  • 17. [The novel coronavirus covid-19 pandemic].
    Cuestas E
    Rev Fac Cien Med Univ Nac Cordoba; 2020 Mar; 77(1):1-3. PubMed ID: 32238250
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.
    Georgakopoulos JR; Yeung J
    J Cutan Med Surg; 2020; 24(4):422-423. PubMed ID: 32434413
    [No Abstract]   [Full Text] [Related]  

  • 19. The Impact of COVID-19 on Italy: A Lesson for the Future.
    Santacroce L; Bottalico L; Charitos IA
    Int J Occup Environ Med; 2020 Jul; 11(3):151-152. PubMed ID: 32225178
    [No Abstract]   [Full Text] [Related]  

  • 20. Poor clinical outcomes for patients with cancer during the COVID-19 pandemic.
    Tang LV; Hu Y
    Lancet Oncol; 2020 Jul; 21(7):862-864. PubMed ID: 32479788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.